ESMO: Eyeing Novartis and Pfizer, Chi-Med touts neuroendocrine cancer win

Pfizer’s Sutent and Novartis’ Afinitor and Lutathera are all approved to tackle certain neuroendocrine tumors, but no one drug covers all types of them. Chi-Med is hoping to change that—and now it has a late-stage clinical win under its belt.